Merck cuts price on AIDS drug Efavirenz

Source: Reuters

By Nopporn Wong-Anan

BANGKOK, Feb 15 (Reuters) - Merck & Co. announced on Thursday price cuts for its HIV-AIDS drug, Efavirenz, in poor countries and those hard hit by the disease, including Thailand which plans to make copycat versions of the medicine.

Thailand, which shocked Merck in November when it announced plans to break the company's patent for Efavirenz, would see its price drop to 700 baht ($19.59) per patient per month.

Merck had previously sold Efavirenz at a non-profit price of 1,300 baht per treatment per month in Thailand, which plans to import Indian-made versions of the drug for 800 baht per month until it is available from Thailand's state-owned drug maker.

"Merck is lowering the price of the 600 mg formulation of Efavirenz due to efficiencies resulting from improved manufacturing processes," the company said.

A spokesman for Merck's Thai subsidiary also attributed the lower Thai price to a more favourable exchange rate.

Last month, the Health Ministry issued compulsory licences for the heart disease drug Plavix, made by Bristol-Myers Squibb and Sanofi-Aventis and Abbott Laboratories' Kaletra to treat HIV/AIDS after a similar move on another AIDS drug last year.

The licences, which Thai health officials said would save the country up to 800 million baht ($24 million) a year, drew praise from AIDS activists but flak from Washington and the drug industry, which are urging the ministry to rescind them.
(...)